Imatinib Mesylate in Treating Patients With Metastatic Melanoma
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an
effective treatment for metastatic melanoma.
PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients
who have metastatic melanoma.